NewLink Genetics Corporation (NLNK) Rating Lowered to Sell at ValuEngine

ValuEngine cut shares of NewLink Genetics Corporation (NASDAQ:NLNK) from a hold rating to a sell rating in a research note issued to investors on Wednesday.

NLNK has been the topic of a number of other research reports. Jefferies Group LLC set a $7.00 price target on shares of NewLink Genetics Corporation and gave the company a hold rating in a research note on Friday, August 25th. Zacks Investment Research raised shares of NewLink Genetics Corporation from a hold rating to a buy rating and set a $12.00 price target on the stock in a research note on Wednesday, June 7th. Cantor Fitzgerald reaffirmed a buy rating and set a $26.00 price target on shares of NewLink Genetics Corporation in a research note on Friday, September 8th. Robert W. Baird raised shares of NewLink Genetics Corporation from a neutral rating to an outperform rating and upped their price target for the company from $8.00 to $22.00 in a research note on Friday, September 8th. Finally, Stifel Nicolaus upped their price target on shares of NewLink Genetics Corporation from $14.00 to $29.00 and gave the company a buy rating in a research note on Monday, September 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $24.17.

NewLink Genetics Corporation (NASDAQ NLNK) traded down 3.94% during trading on Wednesday, hitting $12.67. 4,209,589 shares of the company traded hands. The stock’s market capitalization is $372.76 million. The company’s 50 day moving average is $8.51 and its 200-day moving average is $12.83. NewLink Genetics Corporation has a 52 week low of $5.90 and a 52 week high of $25.17.

NewLink Genetics Corporation (NASDAQ:NLNK) last released its quarterly earnings results on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.78) by $0.21. The company had revenue of $10.37 million for the quarter, compared to the consensus estimate of $2.65 million. NewLink Genetics Corporation had a negative net margin of 161.94% and a negative return on equity of 55.03%. Analysts predict that NewLink Genetics Corporation will post ($2.82) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://transcriptdaily.com/2017/09/17/newlink-genetics-corporation-nlnk-rating-lowered-to-sell-at-valuengine.html.

Hedge funds have recently bought and sold shares of the business. State of Wisconsin Investment Board bought a new position in NewLink Genetics Corporation during the second quarter valued at $125,000. Trexquant Investment LP increased its position in NewLink Genetics Corporation by 39.1% during the second quarter. Trexquant Investment LP now owns 18,132 shares of the biotechnology company’s stock valued at $133,000 after acquiring an additional 5,097 shares during the last quarter. Advisor Group Inc. increased its position in NewLink Genetics Corporation by 3.4% during the second quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock valued at $133,000 after acquiring an additional 600 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in NewLink Genetics Corporation by 3.0% during the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock valued at $140,000 after acquiring an additional 556 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. bought a new position in NewLink Genetics Corporation during the first quarter valued at $145,000. Institutional investors and hedge funds own 54.78% of the company’s stock.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply